Last $19.90 USD
Change Today 0.00 / 0.00%
Volume 0.0
GIKLY On Other Exchanges
Symbol
Exchange
OTC US
OTC US
NASDAQ GS
OTC US
Continuous
Continuous
Frankfurt
Frankfurt
Mexico
As of 8:10 PM 12/16/14 All times are local (Market data is delayed by at least 15 minutes).

grifols sa-spon adr (GIKLY) Snapshot

Open
$19.90
Previous Close
$19.90
Day High
$19.90
Day Low
$19.90
52 Week High
03/6/14 - $29.10
52 Week Low
10/15/14 - $18.40
Market Cap
13.1B
Average Volume 10 Days
41.8
EPS TTM
--
Shares Outstanding
426.1M
EX-Date
12/4/14
P/E TM
--
Dividend
$0.15
Dividend Yield
1.45%
Current Stock Chart for GRIFOLS SA-SPON ADR (GIKLY)

Related News

No related news articles were found.

grifols sa-spon adr (GIKLY) Related Businessweek News

No Related Businessweek News Found

grifols sa-spon adr (GIKLY) Details

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates through four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, such as the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments and reagents for diagnostics, as well as blood bank products. This division primarily serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals, including parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division is involved in the sale of intermediate pastes and plasma products, as well as provision of engineering services to external companies. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

12,615 Employees
Last Reported Date: 04/4/14
Founded in 1940

grifols sa-spon adr (GIKLY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

grifols sa-spon adr (GIKLY) Key Developments

Grifols, S.A. Announces Earnings Results for the Nine Months of 2014

Grifols, S.A. announced earnings results for the nine months of 2014. For the period, the company reported net revenue of EUR 2,438,090,000 against EUR 2,046,563,000 a year ago. Operating profit was EUR 631,221,000 against EUR 566,430,000 a year ago. Profit before tax was EUR 425,927,000 against EUR 385,639,000 a year ago. Consolidated profit for the period was EUR 336,482,000 against EUR 263,942,000 a year ago. EBITDA was EUR 769,756,000 against EUR 662,965,000 a year ago. Adjusted EBITDA was EUR 791,593,000 against EUR 690,367,000 a year ago. Net cash flow from operating activities was EUR 655,888,000 against EUR 365,707,000 a year ago. Free cash flow negative was EUR 779,891,000 against positive free cash flow of EUR 200,854,000 a year ago. CapEx was EUR 180,161,000 against EUR 100,131,000 a year ago.

Grifols, S.A. Approves Interim Dividend for the year 2014

Grifols, S.A. announced that in the meeting held on October 21, 2014, the Board of Directors approved payment of an interim dividend against 2014 profit of euro 0.25 per each share by which the company's share capital is represented. Payment of the interim dividend will be made the first week of December.

Grifols, S.A. to Report Q3, 2014 Results on Nov 04, 2014

Grifols, S.A. announced that they will report Q3, 2014 results Pre-Market on Nov 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GIKLY:US $19.90 USD 0.00

GIKLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $73.00 USD +1.69
Hikma Pharmaceuticals PLC 2,032 GBp -11.00
Hospira Inc $62.66 USD +0.22
STADA Arzneimittel AG €25.80 EUR -0.222
UCB SA €65.79 EUR +0.77
View Industry Companies
 

Industry Analysis

GIKLY

Industry Average

Valuation GIKLY Industry Range
Price/Earnings 26.6x
Price/Sales 3.5x
Price/Book 4.3x
Price/Cash Flow 16.4x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA-SPON ADR, please visit www.grifols.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.